Analyst firms · HSBC · BIIB

HSBC BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

HSBC rates Biogen Inc. (BIIB) Reduce with a $143 price target, as of its latest action on Dec 10, 2025. It has published 3 rating actions on BIIB since September 2023, including 0 upgrades and 2 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. HSBC's $143 is 38% below that.

Current rating
Reduce
Price target
$143
Median target, all firms
$231.50
Actions on BIIB
3

HSBC price target on BIIB

$360$239$118202420252026
HSBC price target on BIIB, each point a stated target, September 2023 to December 2025.

Every HSBC rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about HSBC and BIIB

What is HSBC's price target for BIIB?
HSBC's latest stated price target for Biogen Inc. (BIIB) is $143, from its action on Dec 10, 2025.
What is HSBC's rating on BIIB?
HSBC rates BIIB Reduce, a bearish rating, as of Dec 10, 2025.
When did HSBC last change its view on BIIB?
On Dec 10, 2025, HSBC downgrades to Reduce from Hold, price target $143.
How does HSBC's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. HSBC's $143 is 38% below that.

More BIIB rating histories

All HSBC ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.